The global Kaposi sarcoma market size was estimated to be USD 149.2 million in 2023 and is expected to reach USD 247.6 million by 2034 with a CAGR of 4.71% during the forecast period 2024-2034. The increasing prevalence of HIV/AIDS, advancements in research and development, collaborations and partnerships, rising strategic collaborations and partnerships, and government initiatives and regulatory support will drive the market growth.
Individuals with weakened immune systems, such as those living with HIV/AIDS, are more likely to be diagnosed with Kaposi sarcoma. The need for therapy for Kaposi sarcoma may increase in tandem with the ongoing worry about the global prevalence of HIV/AIDS and its potential impact on incidence. Partnerships among pharmaceutical corporations, academic institutions, and governmental organizations can expedite the creation of novel medications and therapeutic approaches for Kaposi sarcoma. For instance, in September 2023, Phase 2 clinical research was started by Celgene (which Bristol-Myers Squibb bought) to assess the safety and effectiveness of selinexor with paclitaxel for the treatment of relapsed or refractory Kaposi sarcoma.
By type, the epidemic (AIDS-associated) Kaposi sarcoma segment accounted for the highest revenue-grossing segment in the global Kaposi sarcoma market in 2023 owing to the increasing prevalence of HIV/AIDS, heightened research and development activities focused on innovative treatment options, and the implementation of collaborative efforts among pharmaceutical companies, research institutions, and government bodies to address the specific challenges associated with this subset of the disease. For instance, in October 2023, Gilead Sciences and CytRx Corporation signed a partnership agreement to jointly develop and market CYT-TK, a therapy for Kaposi sarcoma. Additionally, the Iatrogenic (transplant-related) Kaposi sarcoma segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing number of organ transplant procedures worldwide, resulting in a larger pool of individuals with suppressed immune systems due to immunosuppressive therapies.
By treatment, the highly active antiretroviral therapy (HAART) segment accounted for the highest revenue-grossing segment in the global Kaposi sarcoma market in 2023 owing to the widespread adoption of comprehensive HIV management strategies. HAART, which effectively suppresses viral replication and helps maintain a stronger immune system, has played a pivotal role in reducing the incidence of AIDS-associated Kaposi sarcoma. For instance, in August 2023, ARQ-531, a promising therapy for Kaposi sarcoma that is presently undergoing Phase 2 clinical trials, was made available to Merck & Co., Inc. through the acquisition of ArQule. Additionally, the immunotherapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of the immune system's role in combating cancer, advancements in immunotherapeutic approaches, and ongoing research efforts focused on developing novel immunomodulatory treatments for Kaposi sarcoma.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global Kaposi sarcoma market in 2023 owing to the central role hospitals play in the diagnosis, treatment, and management of complex oncological conditions. For instance, in December 2023, the FDA of the United States awarded CytRx Corporation's CYT-TK Breakthrough Therapy Designation for the management of recurrent or refractory Kaposi sarcoma. Additionally, the speciality centres segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend towards specialized care and a focus on delivering targeted, patient-centric services for Kaposi sarcoma.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of HIV/AIDS, early adoption of advanced medical technologies, and robust research and development activities. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of Kaposi sarcoma, improving healthcare infrastructure, rising healthcare expenditure, and a growing focus on research and development activities in the field of oncology. For instance, in September 2023, Aphios Corporation's APHS0737 was designated as an Orphan Drug by the European Medicines Agency (EMA) in order to treat Kaposi sarcoma.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Individuals with weakened immune systems, such as those living with HIV/AIDS, are more likely to be diagnosed with Kaposi sarcoma. The need for therapy for Kaposi sarcoma may increase in tandem with the ongoing worry about the global prevalence of HIV/AIDS and its potential impact on incidence. Partnerships among pharmaceutical corporations, academic institutions, and governmental organizations can expedite the creation of novel medications and therapeutic approaches for Kaposi sarcoma. For instance, in September 2023, Phase 2 clinical research was started by Celgene (which Bristol-Myers Squibb bought) to assess the safety and effectiveness of selinexor with paclitaxel for the treatment of relapsed or refractory Kaposi sarcoma.
By type, the epidemic (AIDS-associated) Kaposi sarcoma segment accounted for the highest revenue-grossing segment in the global Kaposi sarcoma market in 2023 owing to the increasing prevalence of HIV/AIDS, heightened research and development activities focused on innovative treatment options, and the implementation of collaborative efforts among pharmaceutical companies, research institutions, and government bodies to address the specific challenges associated with this subset of the disease. For instance, in October 2023, Gilead Sciences and CytRx Corporation signed a partnership agreement to jointly develop and market CYT-TK, a therapy for Kaposi sarcoma. Additionally, the Iatrogenic (transplant-related) Kaposi sarcoma segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing number of organ transplant procedures worldwide, resulting in a larger pool of individuals with suppressed immune systems due to immunosuppressive therapies.
By treatment, the highly active antiretroviral therapy (HAART) segment accounted for the highest revenue-grossing segment in the global Kaposi sarcoma market in 2023 owing to the widespread adoption of comprehensive HIV management strategies. HAART, which effectively suppresses viral replication and helps maintain a stronger immune system, has played a pivotal role in reducing the incidence of AIDS-associated Kaposi sarcoma. For instance, in August 2023, ARQ-531, a promising therapy for Kaposi sarcoma that is presently undergoing Phase 2 clinical trials, was made available to Merck & Co., Inc. through the acquisition of ArQule. Additionally, the immunotherapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing recognition of the immune system's role in combating cancer, advancements in immunotherapeutic approaches, and ongoing research efforts focused on developing novel immunomodulatory treatments for Kaposi sarcoma.
By end-user, the hospital's segment accounted for the highest revenue-grossing segment in the global Kaposi sarcoma market in 2023 owing to the central role hospitals play in the diagnosis, treatment, and management of complex oncological conditions. For instance, in December 2023, the FDA of the United States awarded CytRx Corporation's CYT-TK Breakthrough Therapy Designation for the management of recurrent or refractory Kaposi sarcoma. Additionally, the speciality centres segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing trend towards specialized care and a focus on delivering targeted, patient-centric services for Kaposi sarcoma.
North American region is anticipated to have the highest revenue share during the forecast period owing to the well-established healthcare infrastructure, a high prevalence of HIV/AIDS, early adoption of advanced medical technologies, and robust research and development activities. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the increasing incidence of Kaposi sarcoma, improving healthcare infrastructure, rising healthcare expenditure, and a growing focus on research and development activities in the field of oncology. For instance, in September 2023, Aphios Corporation's APHS0737 was designated as an Orphan Drug by the European Medicines Agency (EMA) in order to treat Kaposi sarcoma.
This comprehensive research report focuses on the global and regional market size and forecasts from 2023 to 2034.
Report Scope:
- Base Year: 2023
- Forecast Period: 2024-2034
- Study Coverage
- Market Forecast by Type, Treatment, and End-User
- Market Forecast for 5 Regions and 17+ Countries
- North America (U.S. and Canada)
- Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
- Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- MEA (South Africa, GCC, Rest of MEA)
- Exhaustive Company Profiles of the Top 10+ Major Market Players
- 20% Free Customization Available to Meet Your Exact Requirement.
Segmentation: Kaposi Sarcoma Market Report 2023 - 2034
Kaposi Sarcoma Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Mn)
- Epidemic (AIDS-associated) Kaposi Sarcoma
- Classic (Mediterranean) Kaposi Sarcoma
- Endemic (African) Kaposi Sarcoma
- Iatrogenic (Transplant-Related) Kaposi Sarcoma
Kaposi Sarcoma Market Analysis & Forecast by Treatment 2023 - 2034 (Revenue USD Mn)
- Highly Active Antiretroviral Therapy (HAART)
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Other Treatments
Kaposi Sarcoma Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Mn)
- Hospitals
- Homecare
- Speciality Centres
- Others
Kaposi Sarcoma Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Mn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Kaposi Sarcoma Market: Type Estimates & Trend Analysis
8. Kaposi Sarcoma Market: TreatmentEstimates & Trend Analysis
9. Kaposi Sarcoma Market: End-User Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Kaposi Sarcoma Market
12. Europe Global Kaposi Sarcoma Market
13. Asia Pacific Global Kaposi Sarcoma Market
14. Latin America Global Kaposi Sarcoma Market
15. MEA Global Kaposi Sarcoma Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Bristol-Myers Squibb
- Merck & Co. Inc.
- F. Hoffmann-La Roche Ltd.
- Johnson & Johnson
- Gilead Sciences Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Eli Lilly and Company
- Novartis International AG
- Celgene Corporation (Acquired by Bristol-Myers Squibb)
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- AbbVie Inc.
- AstraZeneca plc
- Bayer AG.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 149.2 Million |
| Forecasted Market Value ( USD | $ 247.6 Million |
| Compound Annual Growth Rate | 4.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 15 |
